Moderna Is Rising This Morning -- Has Dosed First Clinical Trial Patient, In Newest Bundibugyo/Ebola Vaccine Effort... In Canada (n=80)

We have long been a fan of this well-run, mRNA-science focused biotech.

And as of this morning, it has a vaccine candidate in Phase 1/2 clincial trials, in Canada -- for Bundibugyo. So the stock is rising -- about 3%, on the morning. Sweet. Here's the latest:

. . .Moderna has begun a Phase 1 clinical trial of an Ebola vaccine set to target the Bundibugyo strain, which is currently circulating in the eastern Democratic Republic of the Congo (DRC), the pharmaceutical company announced Tuesday.

The first participants were vaccinated in Canada with the candidate, mRNA-1469. The vaccine will be using the same mRNA platform that Moderna used to develop its vaccine during the COVID-19 pandemic. . . .

Now you know. Onward, grinning -- despite a smallish infestation -- of chuckleheads -- this morning.

नमस्ते